-
'Don't have to hide': Thai IDs, legal work give hope to Myanmar refugees
-
Siemens shares plunge on disappointing guidance raise
-
Stocks mixed with tech firms back under pressure
-
New Australia coach Kiss gives Japan starts to Ross, Amatosero
-
How Blundell's old school tactic ended England's 'Bazball' era
-
'Stretch our money': Romanians face highest EU inflation
-
Israel reports troop deaths as Lebanon talks underway in Rome
-
Iran says close to Hormuz plan with Oman, but reopening depends on US
-
Seeds Rybakina, Pegula, Gauff reach third round at WTA Toronto
-
Messi scores twice to set Leagues Cup record in Miami victory
-
Police raid South Korea FA in probe into World Cup coach appointment
-
Asian stocks mostly down with tech firms back under pressure
-
Low water on Germany's Rhine river threatens new blow to economy
-
Back to the future as world champion Springboks host All Blacks
-
Ex-Wallabies Foley, Phipps rejoin Waratahs ahead of home World Cup
-
India youth protests highlight mistrust in 'lapdog' media
-
Rising Kenyan lakes push crocodiles closer to homes
-
Pacific islands alarmed by Trump-backed push for deep-sea mining
-
Istanbul cymbals: From Ottoman war tool to pulse of global music
-
Erratic rains dictate menu at three-star Michelin restaurant in Brazil
-
Myanmar ex-junta chief on first Thailand trip as civilian leader
-
Zverev, Auger-Aliassime and Medvedev exit Montreal Masters
-
Environmental disaster looms as tanker leaks off Oman
-
Google-parent Alphabet shakes up AI division
-
Embattled Infantino sees minnows Malawi reach WAFCON quarter-finals
-
FIFA back Infantino, apologise for World Cup privatisation plan
-
Seeds Rybakina, Pegula and Gauff advance at WTA Toronto event
-
Auger-Aliassime out of Montreal ATP event with injury
-
Zverev, Auger-Aliassime exit star-short Montreal Masters
-
Colombian baby hippo of Escobar stock dies after rescue
-
Embattled FIFA chief Infantino in emergency talks in Morocco
-
Preakness shifts 2027 dates to entice more Derby horses
-
Castaway SpaceX rocket stage crashed into Moon, scientists say
-
Guatemalan volcano eruption ends, locals return home
-
Dow edges to record as markets parse prospects for Hormuz deal
-
WHO chief urges stronger Ebola response in DR Congo visit
-
Salah arrives in Turkey to complete Trabzonspor move
-
Newcastle appoint Jaissle as new head coach after Howe exit
-
AFP journalist to be honored at International Press Freedom Awards
-
Swiss ski star Lara Gut-Behrami calls time on 18-year career
-
Turkish MPs back limited amnesty for Kurdish militants
-
US indicts leaders of Mexico's CJNG cartel, ups reward money
-
Noosha Aubel: Czy poradzi sobie z problemami Poczdamu?
-
Noosha Aubel: Είναι σε θέση να αντιμετωπίσει τα προβλήματα του Πότσδαμ;
-
Noosha Aubel: Klarar hon av Potsdams problem?
-
نوشا أوبيل: هل هي على مستوى التحديات التي تواجهها بوتسدام؟
-
Noosha Aubel: Zvládne problémy Postupimi?
-
Former England fly-half Burns retires from rugby union
-
Brazil hits new diplomatic lows with US and Argentina
-
Pakistan beat West Indies by eight wickets to level series
UK researchers cure man who had Covid for 411 days
British researchers announced Friday they have cured a man who was continually infected with Covid for 411 days by analysing the genetic code of his particular virus to find the right treatment.
Persistent Covid infection -- which is different to long Covid or repeated bouts of the disease -- occurs in a small number of patients with already weakened immune systems.
These patients can test positive for months or even years with the infection "rumbling along the whole time", said Luke Snell, a physician specialising in infectious diseases at Guy's and St Thomas' NHS Foundation Trust.
The infections can pose a serious threat because around half of patients also have persistent symptoms such as lung inflammation, Snell told AFP, adding that much remains unknown about the condition.
In a new study published in the journal Clinical Infectious Diseases, a team of researchers at Guy's and St Thomas' NHS Foundation Trust and King's College London describe how a 59-year-old man finally overcame his infection after more than 13 months.
The man, who has a weakened immune system due to a kidney transplant, caught Covid in December 2020 and continued to test positive until January this year.
To discover whether he had contracted Covid numerous times or if it was one persistent infection, the researchers used a rapid genetic analysis with nanopore sequencing technology.
The test, which can deliver results in as little as 24 hours, showed the man had an early B.1 variant which was dominant in late 2020 but has since been replaced by newer strains.
Because he had this early variant, the researchers gave him a combination of the casirivimab and imdevimab monoclonal antibodies from Regeneron.
Like most other antibody treatments, the treatment is no longer widely used because it is ineffective against newer variants such as Omicron.
But it successfully cured the man because he was battling a variant from an earlier phase of the pandemic.
- Resistant to treatment -
"The very new variants that are increasing in prevalence now are resistant to all the antibodies available in the UK, the EU and now even the US," Snell said.
The researchers used several such treatments to try to save a seriously ill 60-year-old man in August this year who had been infected since April.
However none worked.
"We really thought he was going to die," Snell said.
So the team crushed up two antiviral treatments not previously used together -- Paxlovid and remdesivir -- and administered them to the unconscious patient via a nasal tube, according to a non-peer-reviewed preprint study on the website ResearchSquare.
"Miraculously he cleared and perhaps this is now the avenue for how we treat these very difficult persistent infections," Snell said, emphasising that this treatment may not translate for normal Covid cases.
At the ECCMID conference in April, the team announced the longest-known persistent infection in a man who tested positive for 505 days before his death.
That "very sad case" came earlier in the pandemic, Snell said, adding that he was grateful there were now so many more treatment options available.
V.F.Barreira--PC